1354691-53-4Relevant articles and documents
Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors
Hoegenauer, Klemens,Soldermann, Nicolas,Zécri, Frédéric,Strang, Ross S.,Graveleau, Nadege,Wolf, Romain M.,Cooke, Nigel G.,Smith, Alexander B.,Hollingworth, Gregory J.,Blanz, Joachim,Gutmann, Sascha,Rummel, Gabriele,Littlewood-Evans, Amanda,Burkhart, Christoph
supporting information, p. 975 - 980 (2017/09/23)
The predominant expression of phosphoinositide 3-kinase δ (PI3Kδ) in leukocytes and its critical role in B and T cell functions led to the hypothesis that selective inhibitors of this isoform would have potential as therapeutics for the treatment of aller
SOLID FORMS AND SALTS OF TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES
-
Page/Page column 40, (2013/03/26)
The invention relates to crystalline anhydrous forms, crystalline solvate forms and/or salt forms including crystalline salt forms of {(S)-3-[6-(6-methoxy-5-methyl-pyridin-3-yl)-5,6,7,8- tetrahydro-pyrido[4,3-d]pyrimidin-4-yloxy]-pyrrolidin-1-yl}-(tetrahydro-pyran-4-yl)-methanone or salt forms including crystalline salt forms of 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl- pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-on; pharmaceutical compositions and combinations including these forms as well as to methods of using these forms, including their pharmaceutical compositions and combinations for the treatment of diseases.
TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES
-
Page/Page column 71, (2012/02/01)
The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which
